{
    "id": "5c8908a475a4a5d21900000c",
    "question": "Is L-4F an apoE mimetic peptide?",
    "options": {
        "A": "yes",
        "B": "no"
    },
    "answer": "B",
    "predict": "To determine if L-4F is an apoE mimetic peptide, we need to analyze the given information. From the documents, we can find the relevant information about apoE and its isoforms. ApoE has three isoforms: apoE2, apoE3, and apoE4. These isoforms differ from each other by a single amino acid. However, we cannot find any information about L-4F being a known apoE isoform or a peptide that mimics apoE. But, we can look for information about L-4F in relation to apoE. After searching the provided documents, we can't find any information about L-4F. However, we can see that apoE4 is mentioned in the context of Alzheimer's disease and its relation to apoE isoforms. Given that L-4F is not mentioned in any of the documents, it's not possible to determine if it's an apoE mimetic peptide based on the provided information. However, we can still use the information about apoE to infer that if L-4F is a peptide that mimics apoE, it would likely be one of the apoE isoforms. Since we can't confirm the nature of L-4F, we can only make an educated guess. Assuming L-4F might be related to apoE, we can consider that apoE4 is a known isoform, but we can't confirm if L-4F is the same or similar. However, without any direct evidence or information about L-4F, we can't provide a definitive answer. Here's the output in json format: {\"step_by_step_thinking\": \"The provided information does not confirm or deny if L-4F is an apoE mimetic peptide. We can only make an educated guess based on the information about apoE isoforms. Without direct evidence, it's not possible to determine if L-4F is an apoE mimetic peptide.\", \"answer_choice\": \"B\"}",
    "snippets": [
        {
            "id": "Biochemistry_Lippincott_816",
            "title": "Biochemistry_Lippinco",
            "content": "Lipoprotein (a), or Lp(a), is nearly identical in structure to an LDL particle. Its distinguishing feature is the presence of an additional apolipoprotein molecule, apo(a), which is covalently linked at a single site to apo B-100. Circulating levels of Lp(a) are determined primarily by genetics. However, factors such as diet may play some role, as trans FA have been reported to increase it. The physiologic function of Lp(a) is unknown. When present in large quantities in the plasma, Lp(a) is associated with an increased risk of coronary heart disease. [Note: Apo(a) is structurally homologous to plasminogen, the precursor of a blood protease whose target is fibrin, the main protein component of blood clots (see Chapter 35 online). It is hypothesized that elevated Lp(a) slows the breakdown of blood clots that trigger heart attacks because it competes with plasminogen for binding to fibrin.] Niacin reduces Lp(a), as well as LDL-C and TAG, and raises HDLC. VII. STEROID HORMONES"
        },
        {
            "id": "Pharmacology_Katzung_3860",
            "title": "Pharmacology_Katzung",
            "content": "E. High-Density Lipoproteins The apoproteins of HDL are secreted largely by the liver and intestine. Much of the lipid comes from the surface monolayers of endothelium Lipoprotein lipase FFA HDL VLDL remnant B-100 ApoC VLDL ApoE HDL LDL Peripheral cell Cholesterol Cholesteryl estersLysosome Acetyl-CoA HMG-CoA reductase Lysosome Cholesterol Mevalonic acid ApoB, ApoE, ApoC RER Golgi vesicle LDL receptor * * Cholesterol biosynthetic pathway"
        },
        {
            "id": "Biochemistry_Lippincott_790",
            "title": "Biochemistry_Lippinco",
            "content": "2. Apolipoproteins: The apolipoproteins associated with lipoprotein particles have a number of diverse functions, such as providing recognition sites for cell-surface receptors and serving as activators or coenzymes for enzymes involved in lipoprotein metabolism. Some of the apolipoproteins are required as essential structural components of the particles and cannot be removed (in fact, the particles cannot be produced without them), whereas others are transferred freely between lipoproteins. Apolipoproteins are divided by structure and function into several major classes, denoted by letters, with each class having subclasses (for example, apolipoprotein [apo] C-I, apo C-II, and apo CIII). [Note: The functions of all the apolipoproteins are not yet known.] B. Chylomicron metabolism"
        },
        {
            "id": "Pharmacology_Katzung_3861",
            "title": "Pharmacology_Katzung",
            "content": "FIGURE 35\u20131 Metabolism of lipoproteins of hepatic origin. The heavy arrows show the primary pathways. Nascent VLDL are secreted via the Golgi apparatus. They acquire additional apo C lipoproteins and apo E from HDL. Very-low-density lipoproteins (VLDL) are converted to VLDL remnants (IDL) by lipolysis via lipoprotein lipase in the vessels of peripheral tissues. In the process, C apolipoproteins and a portion of the apo E are given back to high-density lipoproteins (HDL). Some of the VLDL remnants are converted to LDL by further loss of triglycerides and loss of apo E. A major pathway for LDL degradation involves the endocytosis of LDL by LDL receptors in the liver and the peripheral tissues, for which apo B-100 is the ligand. Dark color denotes cholesteryl esters; light color denotes triglycerides; the asterisk denotes a functional ligand for LDL receptors; triangles indicate apo E; circles and squares represent C apolipoproteins. FFA, free fatty acid; RER, rough endoplasmic"
        },
        {
            "id": "Biochemistry_Lippincott_800",
            "title": "Biochemistry_Lippinco",
            "content": "3. Conversion to low-density lipoproteins: With these modifications, the VLDL is converted in the plasma to LDL. Intermediate-density lipoproteins (IDL) of varying sizes are formed during this transition. IDL can also be taken up by liver cells through receptor-mediated endocytosis that uses apo E as the ligand. Apo E is normally present in three isoforms, E-2 (the least common), E-3 (the most common), and E-4. Apo E-2 binds poorly to receptors, and patients who are homozygotic for apo E-2 are deficient in the clearance of IDL and chylomicron remnants. These individuals have familial type III hyperlipoproteinemia (familial dysbetalipoproteinemia or broad beta disease), with hypercholesterolemia and premature atherosclerosis. [Note: The apo E-4 isoform confers increased susceptibility to an earlier age of onset of the late-onset form of Alzheimer disease. The effect is dose dependent, with homozygotes being at greatest risk. Estimates of the risk vary.]"
        },
        {
            "id": "Biochemistry_Lippincott_38",
            "title": "Biochemistry_Lippinco",
            "content": "1. Naming the peptide: By convention, the free amino end (N-terminal) of the peptide chain is written to the left and the free carboxyl end (C-terminal) to the right. Therefore, all amino acid sequences are read from the N-to the C-terminal end. For example, in Figure 2.2A, the order of the amino acids in the dipeptide is valine, alanine. Linkage of \u226550 amino acids through peptide bonds results in an unbranched chain called a polypeptide, or protein. Each component amino acid is called a residue because it is the portion of the amino acid remaining after the atoms of water are lost in the formation of the peptide bond. When a peptide is named, all amino acid residues have their suffixes (-ine, -an, -ic, or -ate) changed to -yl, with the exception of the C-terminal amino acid. For example, a tripeptide composed of an N-terminal valine, a glycine, and a C-terminal leucine is called valylglycylleucine. 2."
        },
        {
            "id": "Pharmacology_Katzung_3923",
            "title": "Pharmacology_Katzung",
            "content": "Mipomersen is an antisense oligonucleotide that targets apo B-100, mainly in the liver. It is important to note that the apo B-100 gene is also transcribed in the retina and in cardiomyocytes. Subcutaneous injections of mipomersen reduce levels of LDL and Lp(a). Mild to moderate injection site reactions and flu-like symptoms can occur. The drug is available only for use in homozygous familial hypercholesterolemia through a restricted (REMS) program."
        },
        {
            "id": "Biochemistry_Lippincott_837",
            "title": "Biochemistry_Lippinco",
            "content": "dysbetalipoproteinemia. Nascent VLDL are produced in the liver and are composed predominantly of TAG. They contain a single molecule of apo B-100. Like chylomicrons, VLDL receive apo C-II and apo E from HDL in the plasma. VLDL carry hepatic TAG to the peripheral tissues where LPL degrades the lipid. Additionally, the VLDL particle receives cholesteryl esters from HDL in exchange for TAG. This process is accomplished by cholesteryl ester transfer protein (CETP). VLDL in the plasma is first converted to IDL and then to LDL, a much smaller, denser particle. Apo C-II and apo E are returned to HDL, but the LDL retains apo B-100, which is recognized by receptors on peripheral tissues and the liver. LDL undergo receptor-mediated endocytosis, and their contents are degraded in the lysosomes. The protease proprotein convertase subtilisin/kexin type 9 (PCSK9) prevents receptor recycling. Defects in the synthesis of functional LDL receptors causes type IIa hyperlipoproteinemia (familial"
        },
        {
            "id": "InternalMed_Harrison_30218",
            "title": "InternalMed_Harrison",
            "content": "genetic risk factor for sporadic AD and acts as a dose-dependent disease modifier, with the earliest age of onset associated with the \u03b54 homozygosity. Precise mechanisms through which Apo \u03b54 confers AD risk or hastens onset remain unclear, but \u03b54 leads to less efficient amyloid clearance and to the production of toxic fragments from cleavage of the molecule. Apo \u03b5 can be identified in neuritic plaques and may also be involved in neurofibrillary tangle formation, because it binds to tau protein. Apo \u03b54 decreases neurite outgrowth in dorsal root ganglion neuronal cultures, perhaps indicating a deleterious role in the brain\u2019s response to injury. Some evidence suggests that the \u03b52 allele may reduce AD risk. Use of Apo \u03b5 testing in AD diagnosis remains controversial. It is not indicated as a predictive test in normal persons because its precise predictive value is unclear, and many individuals with the \u03b54 allele never develop dementia. Many cognitively normal \u03b54 heterozygotes and"
        },
        {
            "id": "Pharmacology_Katzung_3906",
            "title": "Pharmacology_Katzung",
            "content": "Skeletal muscle Fatty acid oxidation Lipoprotein lipase Endothelium Liver Apo Clll synthesis Apo Al and Apo AII synthesis Fatty acids VLDL, Chylomicron Transcription of LPL vessels Hydrolysis of VLDL and chylomicron triglycerides FIGURE 35\u20134 Hepatic and peripheral effects of fibrates. These effects are mediated by activation of peroxisome proliferator-activated receptor-\u03b1, which decreases the secretion of VLDL and increases its peripheral metabolism. LPL, lipoprotein lipase; VLDL, very-low-density lipoproteins. Niacin (but not niacinamide) decreases triglycerides and LDL levels, and Lp(a) in most patients. It often increases HDL levels significantly. Historically, combination therapy including niacin has been associated with regression of atherosclerotic coronary lesions in three angiographic trials and with extension of lifespan in one large trial in which patients received niacin alone."
        },
        {
            "id": "Biochemistry_Lippincott_808",
            "title": "Biochemistry_Lippinco",
            "content": "E. High-density lipoprotein metabolism HDL comprise a heterogeneous family of lipoproteins with a complex metabolism that is not yet completely understood. HDL particles are formed in the blood by the addition of lipid to apo A-1, an apolipoprotein made and secreted by the liver and intestine. Apo A-1 accounts for ~70% of the apolipoproteins in HDL. HDL perform a number of important functions, including the following. 1. Apolipoprotein supply: HDL particles serve as a circulating reservoir of apo C-II (the apolipoprotein that is transferred to VLDL and chylomicrons and is an activator of LPL) and apo E (the apolipoprotein required for the receptor-mediated endocytosis of IDL and chylomicron remnants). 2."
        },
        {
            "id": "Biochemistry_Lippincott_791",
            "title": "Biochemistry_Lippinco",
            "content": "B. Chylomicron metabolism Chylomicrons are assembled in intestinal mucosal cells and carry dietary (exogenous) TAG, cholesterol, fat-soluble vitamins, and cholesteryl esters to the peripheral tissues (Fig. 18.16). [Note: TAG account for close to 90% of the lipids in a chylomicron.] 1. Apolipoprotein synthesis: Apo B-48 is unique to chylomicrons. Its synthesis begins on the rough ER (RER), and it is glycosylated as it moves through the RER and Golgi. [Note: Apo B-48 is so named because it constitutes the N-terminal 48% of the protein encoded by the gene for apo B. Apo B-100, which is synthesized by the liver and found in VLDL and LDL, represents the entire protein encoded by this gene. Posttranscriptional editing (see p. 474) of a cytosine to a uracil in intestinal apo B-100 messenger RNA (mRNA) creates a nonsense (stop) codon (see p. 449), allowing translation of only 48% of the mRNA.] 2."
        },
        {
            "id": "Biochemistry_Lippincott_798",
            "title": "Biochemistry_Lippinco",
            "content": "Release from the liver: VLDL are secreted directly into the blood by the liver as nascent particles containing apo B-100. They must obtain apo CII and apo E from circulating HDL (see Fig. 18.17). As with chylomicrons, apo C-II is required for activation of LPL. [Note: Abetalipoproteinemia is a rare hypolipoproteinemia caused by a defect in MTP, leading to an inability to load apo B with lipid. Consequently, few VLDL or chylomicrons are formed, and TAG accumulates in the liver and intestine. Absorption of fat-soluble vitamins is decreased. LDL are low.] 2."
        },
        {
            "id": "Biochemistry_Lippincott_793",
            "title": "Biochemistry_Lippinco",
            "content": "Nascent chylomicron modification: The particle released by the intestinal mucosal cell is called a nascent chylomicron because it is functionally incomplete. When it reaches the plasma, the particle is rapidly modified, receiving apo E (which is recognized by hepatic receptors) and apo C. The latter includes apo C-II, which is necessary for the activation of lipoprotein lipase (LPL), the enzyme that degrades the TAG contained in the chylomicron. The source of these apolipoproteins is circulating HDL (see Fig. 18.16). [Note: Apo C-III on TAG-rich lipoproteins inhibits LPL.] 4. Triacylglycerol degradation by lipoprotein lipase: LPL is an extracellular enzyme that is anchored to the capillary walls of most tissues but predominantly those of adipose tissue and cardiac and skeletal muscle."
        },
        {
            "id": "Biochemistry_Lippincott_801",
            "title": "Biochemistry_Lippinco",
            "content": "D. Low-density lipoprotein metabolism LDL particles contain much less TAG than their VLDL predecessors and have a high concentration of cholesterol and cholesteryl esters (Fig. 18.19). About 70% of plasma cholesterol is in LDL. 1. Receptor-mediated endocytosis: The primary function of LDL particles is to provide cholesterol to the peripheral tissues (or return it to the liver). They do so by binding to plasma membrane LDL receptors that recognize apo B-100 (but not apo B-48). Because these LDL receptors can also bind apo E, they are known as apo B-100/apo E receptors. A summary of the uptake and degradation of LDL particles is presented in Figure 18.20. [Note: The numbers in brackets below refer to corresponding numbers on that figure.] A similar mechanism of receptor-mediated endocytosis is used for the uptake and degradation of chylomicron remnants and IDL by the liver."
        },
        {
            "id": "Biochemistry_Lippincott_803",
            "title": "Biochemistry_Lippinco",
            "content": "[2] After binding, the LDL\u2013receptor complex is endocytosed. [Note: Defects in the synthesis of functional LDL receptors causes a significant elevation in plasma LDL-C. Patients with such deficiencies have type IIa hyperlipidemia (familial hypercholesterolemia [FH]) and premature atherosclerosis. Autosomal dominant hypercholesterolemia can also be caused by defects in apo B-100 that reduce its binding to the receptor and by increased activity of a protease, proprotein convertase subtilisin/kexin type 9 (PCSK9), which promotes internalization and lysosomal degradation of the receptor. PCSK9 inhibitors are now available for the treatment of hypercholesterolemia.] [3] The vesicle containing LDL loses its clathrin coat and fuses with other similar vesicles, forming larger vesicles called endosomes."
        },
        {
            "id": "Biochemistry_Lippincott_1673",
            "title": "Biochemistry_Lippinco",
            "content": "A. DNA rearrangement and loss B. DNA transposition C. RNA alternative splicing D. RNA editing E. RNA interference Correct answer = D. The production of apolipoprotein (apo) B-48 in the intestine and apo B-100 in liver is the result of RNA editing in the intestine, where a sense codon is changed to a nonsense codon by posttranscriptional deamination of cytosine to uracil. DNA rearrangement and transposition, as well as RNA interference and alternative splicing, do alter gene expression but are not the basis of apo B-48 tissue-specific production. 3.4. Which of the following is most likely to be true in hemochromatosis, a disease of iron accumulation? A. The messenger RNA for the transferrin receptor is stabilized by the binding of iron regulatory proteins to its 3\u2032-iron-responsive elements. B. The messenger RNA for the transferrin receptor is not bound by iron regulatory proteins and is degraded."
        },
        {
            "id": "Biochemistry_Lippincott_846",
            "title": "Biochemistry_Lippinco",
            "content": "A. Apolipoprotein A-I B. Apolipoprotein B-48 C. Apolipoprotein C-II D. Cholesteryl ester transfer protein E. Microsomal triglyceride transfer protein Correct answer = C. The triacylglycerol (TAG) in chylomicrons is degraded by endothelial lipoprotein lipase (LPL), which requires apolipoprotein (apo) C-II as a coenzyme. Deficiency of LPL or apo C-II results in decreased ability to degrade chylomicrons to their remnants, which get cleared (via apo E) by liver receptors. Apo A-I is the coenzyme for lecithin:cholesterol acyltransferase; apo B-48 is the characteristic structural protein of chylomicrons; cholesteryl ester transfer protein catalyzes the cholesteryl ester\u2013TAG exchange between high-density and very-low-density lipoproteins (VLDL); and microsomal triglyceride transfer protein is involved in the formation, not degradation, of chylomicrons (and VLDL). 8.5. Complete the table below for an individual with classic 21-\u03b1-hydroxylase deficiency relative to a normal individual."
        },
        {
            "id": "Pharmacology_Katzung_3903",
            "title": "Pharmacology_Katzung",
            "content": "Mechanism of Action Fibrates function primarily as ligands for the nuclear transcription receptor PPAR-\u03b1. They transcriptionally upregulate LPL, apo A-I, and apo A-II, and they downregulate apo C-III, an inhibitor of lipolysis. A major effect is an increase in oxidation of fatty acids in liver and striated muscle (Figure 35\u20134). They increase lipolysis of lipoprotein triglyceride via LPL. Intracellular lipolysis in adipose tissue is decreased. Levels of VLDL decrease, in part as a result of decreased secretion by the liver. Only modest reductions of LDL occur in most patients. In others, especially those with combined hyperlipidemia, LDL often increases as triglycerides are reduced. HDL cholesterol increases moderately. Part of this apparent increase is a consequence of lower triglyceride in plasma, resulting in reduction in the exchange of triglycerides into HDL in place of cholesteryl esters."
        },
        {
            "id": "Physiology_Levy_3862",
            "title": "Physiology_Levy",
            "content": "of the remnant particles (ChyR, IDL, and LDL) can vary. In any case the LDL particle is a small, dense, cholesterol-rich particle that is potentially very atherogenic in the face of endothelial damage. LDL particles are safely imported into cells through the LDL receptor. It should be noted that in the conversion of IDL to LDL, the ApoE protein disassociates from the particle. This means that only receptors for which ApoB100 is a ligand can remove LDL from the blood. In contrast to the multiple ApoE receptors, only one receptor, the LDL receptor, can recognize and bind ApoB100. Thus loss or decrease of a functional LDL receptor has significant clinical consequences (see"
        },
        {
            "id": "InternalMed_Harrison_28211",
            "title": "InternalMed_Harrison",
            "content": "familial dySBetalipoproteinemia (fdBl) FDBL (also known as type III hyperlipoproteinemia) is usually a recessive disorder characterized by a mixed hyperlipidemia (elevated cholesterol and TGs) due to the accumulation of remnant lipoprotein particles (chylomicron remnants and VLDL remnants, or IDL). ApoE is present in multiple copies on chylomicron remnants and IDL, and mediates their removal via hepatic lipoprotein receptors (Fig. 421-2). FDBL is due to genetic variants of apoE, most commonly apoE2, that result in an apoE protein with reduced ability to bind lipoprotein receptors. The APOE gene is polymorphic in sequence, resulting in the expression of three common isoforms: apoE3, which is the most common; and apoE2 and apoE4, which both differ from apoE3 by a single amino acid. Although associated with slightly higher LDL-C levels and increased CHD risk, the apoE4 allele is not associated with FDBL. Individuals who carry one or two apoE4 alleles have an increased risk of Alzheimer\u2019s"
        },
        {
            "id": "Biochemistry_Lippincott_306",
            "title": "Biochemistry_Lippinco",
            "content": "Choose the ONE best answer. .1. Which of the following statements best describes glucose? A. It is a C-4 epimer of galactose. B. It is a ketose and usually exists as a furanose ring in solution. C. It is produced from dietary starch by the action of \u03b1-amylase. D. It is utilized in biological systems only in the L-isomeric form. Correct answer = A. Because glucose and galactose differ only in configuration around carbon 4, they are C-4 epimers that are interconvertible by the action of an epimerase. Glucose is an aldose sugar that typically exists as a pyranose ring in solution. Fructose, however, is a ketose with a furanose ring. \u03b1-Amylase does not produce monosaccharides. The D-isomeric form of carbohydrates is the form typically found in biologic systems, in contrast to amino acids that typically are found in the L-isomeric form."
        },
        {
            "id": "Neurology_Adams_8499",
            "title": "Neurology_Adams",
            "content": "It has been clear that an excess or aberrant amyloid alone is an incomplete explanation for the disease. Certain sequence variants in normal genes confer an increased risk of the disease. The one first discovered was Apo E, a regulator of lipid metabolism that has an affinity for A\u03b2 in Alzheimer plaques, has been found to modify the risk of acquiring Alzheimer disease. Of the several isoforms of Apo E, the presence of E4 (and its corresponding allele e4 on chromosome 19) is associated with a tripling of the risk of developing sporadic Alzheimer disease (Roses; Strittmatter et al; Polvikoski et al). This is the same allele that contributes to an elevated low-density lipoprotein fraction in the serum. Possession of two e4 alleles virtually assures the development of disease in those who survive to their eighties. The e4 allele also modifies the age of onset of some of the familial forms of the disease. In contrast, the e2 allele is underrepresented among Alzheimer patients. For these"
        },
        {
            "id": "Biochemistry_Lippincott_1652",
            "title": "Biochemistry_Lippinco",
            "content": "228) and very-low-density lipoproteins ([VLDL] see p. 230). Apo B mRNA is made in the liver and the small intestine. However, in the intestine only, the cytosine (C) base in the CAA codon for glutamine is enzymatically deaminated to uracil (U), changing the sense codon to the nonsense or stop codon UAA, as shown in Figure 33.13. This results in a shorter protein (apo B-48, representing 48% of the message) being made in the intestine (and incorporated into chylomicrons) than is made in the liver (apo B-100, full-length, incorporated into VLDL). U = uracil. 4. Messenger RNA stability: How long an mRNA remains in the cytosol before it is degraded influences how much protein product can be produced from it. Regulation of iron metabolism and the gene-silencing process of RNA interference (RNAi) illustrate the importance of mRNA stability in the regulation of gene expression."
        },
        {
            "id": "Immunology_Janeway_964",
            "title": "Immunology_Janeway",
            "content": "Zhu, Y., Rudensky, A.Y., Corper, A.L., Teyton, L., and Wilson, I.A.: Crystal structure of MHC class II I-Ab in complex with a human CLIP peptide: prediction of an I-Ab peptide-binding motif. J. Mol. Biol. 2003, 326:1157\u20131174. 4-15 MHC class I molecules bind short peptides of 8\u201310 amino acids by both ends. Bouvier, M., and Wiley, D.C.: Importance of peptide amino and carboxyl termini to the stability of MHC class I molecules. Science 1994, 265:398\u2013402. Govindarajan, K.R., Kangueane, P., Tan, T.W., and Ranganathan, S.: MPID: MHC-Peptide Interaction Database for sequence\u2013structure\u2013function information on peptides binding to MHC molecules. Bioinformatics 2003, 19:309\u2013310. Saveanu, L., Fruci, D., and van Endert, P.: Beyond the proteasome: trimming, degradation and generation of MHC class I ligands by auxiliary proteases. Mol. Immunol. 2002, 39:203\u2013215."
        },
        {
            "id": "InternalMed_Harrison_30217",
            "title": "InternalMed_Harrison",
            "content": "The Apo \u03b5 gene on chromosome 19 is involved in the pathogenesis of AD. The protein, apolipoprotein E, participates in cholesterol transport (Chap. 421), and the gene has three alleles: \u03b52, \u03b53, and \u03b54. The Apo \u03b54 allele confers increased risk of AD in the general population, including sporadic and late-age-of-onset familial forms. Approximately 24\u201330% of the nondemented white population has at least one \u03b54 allele (12\u201315% allele frequency), and about 2% are \u03b54/\u03b54 homozygotes. Among patients with AD, 40\u201365% have at least one \u03b54 allele, a highly significant elevation compared with controls. Conversely, many AD patients have no \u03b54 allele, and \u03b54 carriers may never develop AD. Therefore, \u03b54 is neither necessary nor sufficient to cause AD. Nevertheless, the Apo \u03b54 allele represents the most important genetic risk factor for sporadic AD and acts as a dose-dependent disease modifier, with the earliest age of onset associated with the \u03b54 homozygosity. Precise mechanisms through which Apo \u03b54"
        },
        {
            "id": "First_Aid_Step1_583",
            "title": "First_Aid_Step1",
            "content": "ACh. Associated with the following altered proteins: ApoE-2: \u0090 risk of sporadic form ApoE-4: \u008f risk of sporadic form \u2022 APP, presenilin-1, presenilin-2: familial forms (10%) with earlier onset Widespread cortical atrophy (normal cortex B ; cortex in Alzheimer disease C ), especially hippocampus (arrows in B and C ). Narrowing of gyri and widening of sulci. Senile plaques D in gray matter: extracellular \u03b2-amyloid core; may cause amyloid angiopathy \u008e intracranial hemorrhage; A\u03b2 (amyloid-\u03b2) synthesized by cleaving amyloid precursor protein (APP). E : intracellular, hyperphosphorylated tau protein = insoluble cytoskeletal elements; number of tangles correlates with degree of dementia. Hirano bodies\u2014intracellular eosinophilic proteinaceous rods in hippocampus. Formerly called Pick disease. Early changes in Frontotemporal lobe degeneration"
        },
        {
            "id": "Biochemistry_Lippincott_1869",
            "title": "Biochemistry_Lippinco",
            "content": "TQ1.The phenotype would be the same. In familial defective apolipoprotein (apo) B-100, LDL receptors are normal in number and function, but the ligand for the receptor is altered such that binding to the receptor is decreased. Decreased ligand\u2013receptor binding results in increased levels of LDL in the blood with hypercholesterolemia. [Note: The phenotype would be the same in individuals with a gain-of-function mutation to PCSK9, the protease that decreases recycling of the LDL receptor, thereby increasing its degradation.] With the apo E-2 isoform, cholesterol-rich chylomicron remnants and intermediate-density lipoproteins would accumulate in blood. TQ2.Aspirin irreversibly inhibits cyclooxygenase (COX) and, therefore, the synthesis of prostaglandins (PG), such as PGI2 in vascular endothelial cells, and thromboxanes (TX), such as TXA2 in activated platelets. TXA2 promotes vasoconstriction and formation of a platelet plug, whereas PGI2 inhibits these events. Because platelets are"
        },
        {
            "id": "InternalMed_Harrison_28147",
            "title": "InternalMed_Harrison",
            "content": "Lp(a) is a lipoprotein similar to LDL in lipid and pro tein composition, but it contains an additional protein called apolipoprotein(a) [apo(a)]. Apo(a) is synthesized IDL in the liver and attached to apoB-100 by a disulfide link- Disorders of Lipoprotein Metabolism age. The major site of clearance of Lp(a) is the liver, but the uptake pathway is not known."
        },
        {
            "id": "Biochemistry_Lippincott_788",
            "title": "Biochemistry_Lippinco",
            "content": "A. Composition Lipoproteins are composed of a neutral lipid core (containing TAG and cholesteryl esters) surrounded by a shell of amphipathic apolipoproteins, phospholipid, and nonesterified (free) cholesterol (Fig. 18.14). These amphipathic compounds are oriented such that their polar portions are exposed on the surface of the lipoprotein, thereby rendering the particle soluble in aqueous solution. The TAG and cholesterol carried by the lipoproteins are obtained either from the diet (exogenous source) or from de novo synthesis (endogenous source). [Note: The cholesterol (C) content of plasma lipoproteins is now routinely measured in fasting blood. Total C = LDL-C + HDL-C + VLDL-C, where VLDL-C is calculated by dividing TAG by 5 because the TAG/cholesterol ratio is 5/1 in VLDL. The goal value for total cholesterol is <200 mg/dl.] 1."
        },
        {
            "id": "InternalMed_Harrison_28136",
            "title": "InternalMed_Harrison",
            "content": "ApoA-I Intestine, liver ApoA-IV Intestine, ApoC-I Liver ApoC-II Liver ApoC-III Liver, HDL, chylomicrons HDL, chylomicrons HDL, chylomicrons VLDL, chylomicrons Chylomicrons, chylomicron remnants VLDL, IDL, LDL, Lp(a) Chylomicrons, VLDL, HDL Chylomicrons, VLDL, HDL Chylomicrons, VLDL, HDL Chylomicron remnants, IDL, HDL Structural protein for HDL Structural protein for VLDL, LDL, IDL, Lp(a) Ligand for binding to LDL receptor Inhibits LPL activity and lipoprotein binding to receptors Ligand for binding to LDL receptor and other receptors Abbreviations: HDL, high-density lipoprotein; IDL, intermediate-density lipoprotein; LCAT, lecithin-cholesterol acyltransferase; LDL, low-density lipoprotein; Lp(a), lipoprotein A; LPL, lipoprotein lipase; VLDL, very-low-density lipoprotein."
        },
        {
            "id": "Immunology_Janeway_895",
            "title": "Immunology_Janeway",
            "content": "Fig. 4.21 Peptides bind to MHC molecules through structurally related anchor residues. Peptides eluted from two different Mhc class i molecules are shown in the upper and lower panels, respectively. The anchor residues (green) differ for peptides that bind different allelic variants of Mhc class i molecules but are similar for all peptides that bind to the same Mhc molecule. The anchor residues that bind a particular Mhc molecule need not be identical, but are always related: for example, phenylalanine (f) and tyrosine (Y) are both aromatic amino acids, whereas valine (V), leucine (L), and isoleucine (i) are all large hydrophobic amino acids. Peptides also bind to Mhc class i molecules through their amino (blue) and carboxy (red) termini."
        }
    ],
    "scores": [
        0.02830669128101837,
        0.02612102068623808,
        0.02401640079441348,
        0.019230769230769232,
        0.01916024935826916,
        0.01786843769765971,
        0.017322718561108653,
        0.01700800793707037,
        0.016807909604519774,
        0.01647457627118644,
        0.016471695576173187,
        0.016388047913650124,
        0.016339869281045753,
        0.016335978835978836,
        0.015763076188201577,
        0.015543738678197862,
        0.015417457305502846,
        0.015347151432778344,
        0.015288919893035694,
        0.015252676413030965,
        0.014831869779396016,
        0.014723330816524646,
        0.014642857142857141,
        0.014623587794319503,
        0.01411764705882353,
        0.013858195211786372,
        0.013616357968090959,
        0.013563671355908904,
        0.013374125874125875,
        0.013289183222958058,
        0.013167013167013167,
        0.012847446670976082
    ]
}